Freeze-dried preparation of cell factor (Noggin) and preparation process

By adding appropriate buffers, excipients and surfactants to the Noggin protein lyophilized preparation and adopting a specific lyophilized process, the problem of poor stability of Noggin protein is solved, and a stable and easy-to-storage lyophilized preparation is prepared. The high quality and stability of the lyophilized preparation are achieved.

CN118986901APending Publication Date: 2024-11-22BAIFAN BIOTECHNOLOGY (SHANGHAI) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410452303.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-04-16
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The poor stability of Noggin protein leads to instable storage and is difficult to be safe and effective for mammal treatment.

Method used

Using lyophilized preparations including Noggin protein, buffers, excipients, stabilizers and surfactants, a stable cytokine (Noggin) lyophilized preparation is prepared through specific ratios and lyophilized processes to ensure that the preparation is stored. and stability in transportation.

Benefits of technology

The prepared Noggin protein lyophilized preparation has a plump appearance, uniform texture, and is easy to redissolve. The pH, osmotic pressure, color, clarity, purity and activity index are better than the existing technology. The lyophilized process is simple, suitable for amplification and good drying effect. , convenient storage and transportation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118986901A_ABST
    Figure CN118986901A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biological pharmacy, and discloses a freeze-dried preparation of a cell factor (Noggin) and a preparation process. The preparation process of the freeze-dried preparation of the cell factor (Noggin) comprises the following steps: S1, pre-freezing; s2, sublimation drying: vacuumizing to 0.1-0.2 mbar, heating to-35 DEG C to-15 DEG C, setting time for 1-1.5 hours to reach a preset temperature, and maintaining for 20-50 hours; and S3, desorption drying: raising the temperature to 20-35 DEG C, setting the time to be 2-3 hours to reach a preset temperature, maintaining the temperature for 6-10 hours, carrying out desorption drying, and maintaining the vacuum degree to be 0.1-0.2 mbar at the same time, thereby finishing freeze-drying. The Noggin protein freeze-dried preparation prepared by the invention is simple in preparation process, suitable for amplification, stable and controllable in quality, good in drying effect, low in moisture content of freeze-dried powder, and convenient to store and transport.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biopharmaceuticals, and specifically relates to a cytokine (Noggin) protein freeze-dried preparation and a preparation process thereof. Background Art

[0002] Noggin is a glycoprotein. In recent years, many studies have pointed out that Noggin is related to neurological diseases such as Alzheimer's disease, ischemic stroke, and Parkinson's disease. Noggin is a neural inducer that works by antagonizing bone morphogenetic protein 4 (BMP4). It plays a role in the maturation of the nervous system and the development of embryonic tissues by mediating signal pathways such as bone morphogenetic protein (BMP), Wnt, and Notch. Some scholars have found that Noggin protein is expressed to varying degrees in the cerebral cortex, hippocampus, hypothalamus, brainstem, and cerebellum of adult mammals. These findings suggest that the signal network composed of Noggin and BMP4 signal pathways jointly regulates the development, differentiation, and plasticity of the nervous system and plays a continuous role. Noggin not only plays a role in the development of the mammalian nervous system, but also can specifically bind to and inhibit BMPs. It plays an important role in the early development of the embryo and the formation of limbs, and plays an important role in the formation of bones, cartilage, and joints of the body. In the development of the jaw, Noggin maintains the normal development of the mandible by antagonizing BMPs. In addition, the physiological function of Noggin may be more complex than it appears. Studies have found that knocking out the Nog gene in mice will lead to joint loss and short, continuous limbs. Overexpression of the Nog gene in mice through transgenic technology will lead to reduced trabecular formation, reduced bone mass, and even fractures. These experimental results suggest that excessive or low expression of Noggin will cause various adverse manifestations in the body.

[0003] However, since Noggin is a dimer structure, its stability is more complicated than the general chemical and physical degradation pathways. Therefore, a lyophilized preparation that can stably store Noggin is prepared so that it can be safely and effectively used for the treatment of mammals, especially for humans. Therefore, a stable lyophilized preparation of cytokine (Noggin) is proposed. Summary of the invention

[0004] The purpose of the present invention is to provide a lyophilized preparation of cytokine (Noggin) and a lyophilization process to solve the technical problem of poor storage stability of Noggin. To achieve the above purpose, the present invention provides the following technical solutions: A lyophilized preparation of a cytokine (Noggin), comprising Noggin protein, a buffer system, an excipient, a stabilizer and a surfactant; the Noggin protein is 0.1 mg / ml Noggin protein; the buffer system comprises a buffer and water for injection, the buffer comprising but not limited to histidine-histidine hydrochloride, citric acid-sodium citrate; the excipient comprises but not limited to one or more of trehalose, sucrose, mannitol or sorbitol; the stabilizer is povidone K30; the surfactant comprises but not limited to polysorbate 80 or polysorbate 20.

[0005] Preferably, the cytokine (Noggin) preparation before lyophilization and after reconstitution includes the following components in terms of concentration: Noggin protein 0.1 mg / ml, buffer 10-30 mmol / L, excipient 200-260 mmol / L, stabilizer 10-50 mmol / L, surfactant 0.02-0.06% (w / v), and the buffer system pH is 5.5-6.5.

[0006] Further preferably, the cytokine (Noggin) preparation before lyophilization and after reconstitution comprises the following components in terms of concentration: Noggin protein 0.1 mg / ml, histidine-histidine hydrochloride buffer solution 10-30 mmol / L, sucrose 200-260 mmol / L, povidone K30 20-30 mmol / L, polysorbate 80 0.02-0.06% (w / v), and the buffer system pH is 6.0-6.5.

[0007] Further preferably, the content of Noggin protein is 0.1 mg / ml; the concentration of histidine-histidine hydrochloride buffer solution is 20 mmol / L; the concentration of sucrose is 230 mmol / L; the concentration of povidone K30 is 30 mmol / L; the content of polysorbate 80 is 0.02% (w / v); and the pH is 6.0.

[0008] The preparation process of the semi-finished solution of the cytokine (Noggin) comprises the following steps: Step 1: Weigh the prescribed amount of histidine-histidine hydrochloride buffer, dissolve it in an appropriate amount of water for injection, and adjust the pH; Step 2: After sampling and testing the pH and endotoxin, the cytokine (Noggin) is ultrafiltered and concentrated using the buffer system prepared in step 1 to replace the original buffer system of the Noggin protein, and then the prescribed amount of povidone K30, sucrose and polysorbate 80 are added, stirred evenly, and then the protein concentration is adjusted to 0.1 mg / ml using the buffer system. The semi-finished liquid is mixed evenly to obtain the semi-finished liquid, which is aseptically filtered using a 0.22 μm filter membrane, and filled into a vial after the endotoxin test is qualified, and freeze-dried to obtain the product.

[0009] The present invention also provides a freeze-drying process for a cytokine (Noggin) freeze-dried preparation, comprising the following steps: S1: Pre-freezing: First, place the vial containing the sample of the freeze-dried preparation on the freeze dryer partition at 0-5°C for pre-cooling, set 10-30 minutes to reach the preset temperature, maintain for 0.5-1h, cool to -45--40°C, set time 1-2h to reach the preset temperature, maintain for 1-3h to freeze; S2: Sublimation drying: evacuate to 0.1-0.2 mbar, heat to -35℃~-15℃, set time 1~1.5h to reach preset temperature, maintain for 20-50h; S3: Desorption and drying: Heat to 20-35°C, set time 2-3h to reach the preset temperature, maintain 6-10h for desorption and drying, while maintaining vacuum degree 0.1-0.2mbar, freeze drying is completed.

[0010] Preferably, the freeze-drying process of the Noggin freeze-dried preparation adopts the following steps: S1: Pre-freezing: First, place the vial containing the sample of the freeze-dried preparation on the freeze dryer partition at 5°C for pre-cooling, set it to reach the preset temperature for 0.5h, maintain it for 1h, cool it down to -45~-40°C, set it to reach the preset temperature for 100min, maintain it for 2h for freezing; S2: Sublimation drying: Heat to -35℃~-15℃, set time 60~80min to reach the preset temperature, maintain for 30h, and maintain vacuum degree 0.1mbar to complete sublimation drying; S3: Desorption and drying: Heat to 20-35°C, set time 150min to reach the preset temperature, maintain for 8h for desorption and drying, while maintaining vacuum degree 0.1mbar, freeze drying is completed.

[0011] Compared with the prior art, the present invention has the following beneficial effects: 1. The Noggin protein freeze-dried preparation prepared by the present invention has a simple auxiliary material ratio, which further reduces the potential safety hazards of clinical medication.

[0012] 2. The Noggin freeze-dried preparation prepared by the present invention has a full appearance, uniform texture, and is easy to reconstitute. Its pH, osmotic pressure, color, clarity, purity, activity and other indicators all meet the quality standards and are superior to the prior art.

[0013] 3. The Noggin protein freeze-dried preparation prepared by the present invention has a simple preparation process, is suitable for scale-up, has stable and controllable quality, has a good drying effect, has a low moisture content in the freeze-dried powder, and is convenient for storage and transportation. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] Figure 1This is a process flow chart of the preparation of the cytokine (Noggin) freeze-dried preparation of the present invention; Figure 2 is a Tm (melting temperature) test line graph of the present invention; Figure 3 It is a bar graph of Tagg (aggregation onset temperature) test of the present invention. DETAILED DESCRIPTION

[0015] The present invention is further illustrated by way of examples below. The listed cases are only part of the preparation screening test, and the present invention cannot be limited to the scope of the examples. The experimental methods without specific conditions in the following examples are selected according to conventional methods and conditions or according to the product instructions. The stability test in the example is selected, and the relevant biological tests are carried out according to the specifications of the Chinese Pharmacopoeia. The reagents described in the examples are all pharmaceutical grade and can be obtained through commercial channels. Example

[0016] (1) Prescription: 0.1 mg / ml Noggin protein, 30 mmol / L histidine-histidine hydrochloride, 250 mmol / L sucrose, 50 mmol / L povidone K30, 0.02% (w / v) polysorbate 20, buffer system adjusted to pH 6.5.

[0017] (2) The preparation process of the cytokine (Noggin) protein semi-finished product solution comprises the following steps: Step 1: Prepare the buffer system: weigh the prescribed amount of histidine-histidine hydrochloride buffer, add injection water to dissolve, and adjust the pH; Step 2: Use the buffer system prepared in step 1 to ultrafilter and concentrate the stock solution of cytokine (Noggin), replace the original buffer system of cytokine (Noggin) protein, add the prescribed amount of povidone K30, sucrose and polysorbate 20, and then use the buffer system to adjust the protein concentration to 0.1 mg / ml, mix evenly to obtain a semi-finished liquid, sterile filter the semi-finished liquid with a 0.22 μm filter membrane, fill it into a vial after endotoxin testing is qualified, and freeze-dry it according to the following freeze-drying process.

[0018] The freeze-drying process is designed as follows: S1: Pre-freezing: First, place the vial containing the cytokine (Noggin) protein solution on the freeze dryer partition, set the temperature to 5°C for pre-freezing, set the time to 30 minutes to reach the preset temperature, maintain it for 0.5 hours, then cool it to -45°C, set the time to 1 hour to reach the preset temperature, and maintain it for 2 hours for freezing; S2: Sublimation drying: Raise the temperature of the partition system to -20°C, set the time to reach the preset temperature for 1 hour, maintain it for 40 hours, and maintain the vacuum degree at 0.1 mbar to complete sublimation drying; S3: analytical drying: the temperature of the partition system is raised to 25°C, and the set time is 1.5 hours to reach the preset temperature, and maintained for 10 hours for drying, while maintaining the vacuum degree of 0.1 mbar, and the freeze-drying is completed. Example

[0019] (1) Prescription: 0.1 mg / ml Noggin protein, 30 mmol / L histidine-histidine hydrochloride, 250 mmol / L mannitol, 20 mmol / L povidone K30, 0.02% (w / v) polysorbate 20, buffer system adjusted to pH 6.5.

[0020] (2) The preparation process of the cytokine (Noggin) protein semi-finished product solution comprises the following steps: Step 1: Prepare the buffer system: weigh the prescribed amount of histidine-histidine hydrochloride buffer, add injection water to dissolve, and adjust the pH; Step 2: Use the buffer system prepared in step 1 to ultrafilter and concentrate the stock solution of cytokine (Noggin), replace the original buffer system of cytokine (Noggin) protein, then add the prescribed amount of povidone K30, mannitol and polysorbate 20, and then use the buffer system to adjust the protein concentration to 0.1 mg / ml, mix evenly to obtain a semi-finished liquid, sterile filter the semi-finished liquid with a 0.22 μm filter membrane, fill it into a vial after endotoxin testing is qualified, and freeze-dry it according to the freeze-drying process of Example 1. Example

[0021] (1) Prescription: 0.1 mg / ml Noggin protein, 30 mmol / L histidine-histidine hydrochloride, 250 mmol / L trehalose, 20 mmol / L povidone K30, 0.02% (w / v) polysorbate 20, buffer system adjusted to pH 6.5.

[0022] (2) The preparation process of the cytokine (Noggin) protein semi-finished product solution comprises the following steps: Step 1: Prepare the buffer system: weigh the prescribed amount of histidine-histidine hydrochloride buffer, add injection water to dissolve, and adjust the pH; Step 2: Use the buffer system prepared in step 1 to ultrafilter and concentrate the stock solution of cytokine (Noggin), replace the original buffer system of cytokine (Noggin) protein, then add the prescribed amount of povidone K30, trehalose and polysorbate 20, and then use the buffer system to adjust the protein concentration to 0.1 mg / ml, mix evenly to obtain a semi-finished liquid, sterile filter the semi-finished liquid with a 0.22 μm filter membrane, fill it into a vial after endotoxin detection, and freeze-dry it according to the freeze-drying process of Example 1. Example

[0023] (1) Prescription: 0.1 mg / ml Noggin protein, 20 mmol / L histidine-histidine hydrochloride, 250 mmol / L sucrose, 40 mmol / L povidone K30, 0.02% (w / v) polysorbate 80, buffer system adjusted to pH 6.0.

[0024] (2) The preparation process of the cytokine (Noggin) protein semi-finished product solution comprises the following steps: Step 1: Prepare the buffer system: weigh the prescribed amount of histidine-histidine hydrochloride buffer, add injection water to dissolve, and adjust the pH; Step 2: Use the buffer system prepared in step 1 to ultrafilter and concentrate the stock solution of cytokine (Noggin), replace the original buffer system of cytokine (Noggin) protein, add the prescribed amount of povidone K30, sucrose and polysorbate 80, and then use the buffer system to adjust the protein concentration to 0.1 mg / ml, mix evenly to obtain a semi-finished liquid, sterile filter the semi-finished liquid with a 0.22 μm filter membrane, fill it into a vial after endotoxin testing is qualified, and freeze-dry it according to the following freeze-drying process.

[0025] The freeze-drying process is designed as follows: S1: Pre-freezing: First, place the vial containing the cytokine (Noggin) protein solution on the freeze dryer partition, set the temperature to 5°C for pre-freezing, set the time to 30 minutes to reach the preset temperature, maintain it for 0.5 hours, then cool it to -45°C, set the time to 1.5 hours to reach the preset temperature, and maintain it for 2 hours for freezing; S2: Sublimation drying: The temperature of the partition system is raised to -15°C, and the set time is 1 hour to reach the preset temperature, and maintained for 30 hours, while maintaining the vacuum degree of 0.1 mbar to complete sublimation drying; S3: analytical drying: the temperature of the partition system is raised to 25°C, and the set time is 1.5 hours to reach the preset temperature, and maintained for 8 hours for drying, while maintaining the vacuum degree of 0.1 mbar, and the freeze-drying is completed. Example

[0026] (1) Prescription: 0.1 mg / ml Noggin protein, 20 mmol / L histidine-histidine hydrochloride, 230 mmol / L sucrose, 30 mmol / L povidone K30, 0.02% (w / v) polysorbate 80, buffer system adjusted to pH 6.0.

[0027] (2) The preparation process of the cytokine (Noggin) protein semi-finished product solution comprises the following steps: Step 1: Prepare the buffer system: weigh the prescribed amount of histidine-histidine hydrochloride buffer, add injection water to dissolve, and adjust the pH; Step 2: Use the buffer system prepared in step 1 to ultrafilter and concentrate the stock solution of cytokine (Noggin), replace the original buffer system of cytokine (Noggin) protein, then add the prescribed amount of povidone K30, sucrose and polysorbate 80, and then use the buffer system to adjust the protein concentration to 0.1 mg / ml, mix evenly to obtain a semi-finished liquid, and sterile filter the semi-finished liquid with a 0.22 μm filter membrane, fill it into a vial after endotoxin detection, and freeze-dry it according to the freeze-drying process of Example 4.

[0028] The lyophilized preparation provided above can maintain stability during storage and has lower aggregation and fragmentation; after being placed at 2-8°C for 24 months, there is no significant change in the appearance, concentration, pH and antibody purity of the preparation. Example

[0029] (1) Prescription: 0.1 mg / ml Noggin protein, 20 mmol / L histidine-histidine hydrochloride, 230 mmol / L trehalose, 30 mmol / L povidone K30, 0.02% (w / v) polysorbate 80, buffer system adjusted to pH 6.0.

[0030] (2) The preparation process of the cytokine (Noggin) protein semi-finished product solution comprises the following steps: Step 1: Prepare the buffer system: weigh the prescribed amount of histidine-histidine hydrochloride buffer, add injection water to dissolve, and adjust the pH; Step 2: Use the buffer system prepared in step 1 to ultrafilter and concentrate the stock solution of cytokine (Noggin), replace the original buffer system of cytokine (Noggin) protein, add the prescribed amount of povidone K30, trehalose and polysorbate 20, and then use the buffer system to adjust the protein concentration to 0.1 mg / ml, mix evenly to obtain a semi-finished liquid, sterile filter the semi-finished liquid with a 0.22 μm filter membrane, fill it into a vial after endotoxin detection, and freeze-dry it according to the freeze-drying process of Example 4. Example

[0031] (1) Prescription: 0.1 mg / ml Noggin protein, 20 mmol / L citric acid-sodium citrate, 230 mmol / L sucrose, 30 mmol / L povidone K30, 0.02% (w / v) polysorbate 80, buffer system adjusted to pH 6.0.

[0032] (2) The preparation process of the cytokine (Noggin) protein semi-finished product solution comprises the following steps: Step 1: Prepare the buffer system: weigh the prescribed amount of citric acid-sodium citrate buffer, add injection water to dissolve, and adjust the pH; Step 2: Use the buffer system prepared in step 1 to ultrafilter and concentrate the stock solution of cytokine (Noggin), replace the original buffer system of cytokine (Noggin) protein, add the prescribed amount of povidone K30, sucrose and polysorbate 80, and then use the buffer system to adjust the protein concentration to 0.1 mg / ml, mix evenly to obtain a semi-finished liquid, sterile filter the semi-finished liquid with a 0.22 μm filter membrane, fill it into a vial after endotoxin detection, and freeze-dry it according to the freeze-drying process of Example 4. Example

[0033] (1) Prescription: 0.1 mg / ml Noggin protein, 20 mmol / L histidine-histidine hydrochloride, 230 mmol / L sucrose, 0.02% (w / v) polysorbate 80, buffer system adjusted to pH 6.0.

[0034] (2) The preparation process of the cytokine (Noggin) protein semi-finished product solution comprises the following steps: Step 1: Prepare the buffer system: weigh the prescribed amount of histidine-histidine hydrochloride buffer, add injection water to dissolve, and adjust the pH; Step 2: Use the buffer system prepared in step 1 to ultrafilter and concentrate the stock solution of cytokine (Noggin), replace the original buffer system of cytokine (Noggin) protein, add the prescribed amount of sucrose and polysorbate 80, and then use the buffer system to adjust the protein concentration to 0.1 mg / ml, mix evenly to obtain a semi-finished liquid, and sterile filter the semi-finished liquid with a 0.22 μm filter membrane, fill it into a vial after endotoxin testing is qualified, and freeze-dry it according to the freeze-drying process of Example 4.

[0035] 1. Tm (melting temperature) and Tagg (aggregation onset temperature) value test The Tm (melting temperature) and Tagg (aggregation onset temperature) values ​​of Examples 1-8 were measured using nanoDSF technology. The experimental results are shown in Table 1: Table 1 NogginTm, Tagg detection results

[0036] 2. Stability test Prepare samples according to Examples 1-8, and use accelerated stability tests and long-term tests to examine the storage stability of the protein. The long-term test was carried out at 2-8°C, at the end of 0 months, 3 months, 6 months, 12 months, and 24 months; the accelerated test was carried out at 25°C±2°C for 12 months; the equipment used can control the temperature by ±2°C and monitor the actual temperature. Samples were taken at the end of 0 months, 3 months, 6 months, and 12 months during the test, and tested according to the key stability inspection items. The test results are shown in Tables 2 and 3: Table 2 Results of long-term stability test at 2~8℃

[0037] Table 3 Results of accelerated stability test at 25℃

[0038]

[0039] From the test results in Table 1, Table 2 and Table 3, it can be seen that the freeze-dried preparation of the cytokine (Noggin) prepared by the present invention has a low moisture content, can maintain stability during storage, and has low aggregation and fragmentation; after being placed at 2-8°C for 24 months, the appearance, concentration, pH and antibody purity of the preparation have no obvious changes.

[0040] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A lyophilized preparation of cytokine (Noggin), characterized in that It includes Noggin protein, buffer system, excipient, stabilizer and surfactant; The Noggin protein is 0.1 mg / ml Noggin protein; the buffer system includes a buffer and water for injection, and the buffer includes but is not limited to histidine-histidine hydrochloride, citric acid-sodium citrate; the excipient includes but is not limited to one or more of trehalose, sucrose, mannitol or sorbitol; the stabilizer is povidone K30; the surfactant includes but is not limited to polysorbate 80 or polysorbate 20.

2. The lyophilized preparation of cytokine (Noggin) according to claim 1, characterized in that The cytokine (Noggin) preparation before freeze-drying and after reconstitution includes the following components in terms of concentration: Noggin protein 0.1 mg / ml, buffer 10-30 mmol / L, excipient 200-260 mmol / L, stabilizer 10-50 mmol / L, surfactant 0.02-0.06% (w / v), and the pH of the buffer system is 5.5-6.

5.

3. The lyophilized preparation of cytokine (Noggin) according to claim 1, characterized in that The cytokine (Noggin) preparation before freeze-drying and after reconstitution includes the following components in terms of concentration: Noggin protein 0.1 mg / ml, histidine-histidine hydrochloride buffer solution 10-30 mmol / L, sucrose 200-260 mmol / L, povidone K30 20-30 mmol / L, polysorbate 80 0.02-0.06% (w / v), and the buffer system pH is 6.0-6.

5.

4. The lyophilized preparation of cytokine (Noggin) according to claim 1, characterized in that: The content of Noggin protein is 0.1 mg / ml; the concentration of histidine-histidine hydrochloride buffer solution is 20 mmol / L; the concentration of sucrose is 230 mmol / L; the concentration of povidone K30 is 30 mmol / L; the content of polysorbate 80 is 0.02% (w / v); and the pH is 6.

0.

5. The lyophilized preparation of cytokine (Noggin) according to claim 1, characterized in that The preparation process of the semi-finished solution of the cytokine (Noggin) comprises the following steps: Step 1: Weigh the prescribed amount of histidine-histidine hydrochloride buffer, dissolve it in an appropriate amount of water for injection, and adjust the pH; Step 2: After sampling and testing the pH and endotoxin, the cytokine (Noggin) is ultrafiltered and concentrated using the buffer system prepared in step 1 to replace the original buffer system of the Noggin protein, and then the prescribed amount of povidone K30, sucrose and polysorbate 80 are added, stirred evenly, and then the protein concentration is adjusted to 0.1 mg / ml using the buffer system. The semi-finished liquid is mixed evenly to obtain the semi-finished liquid, which is aseptically filtered using a 0.22 μm filter membrane, and filled into a vial after the endotoxin test is qualified, and freeze-dried to obtain the product.

6. A process for preparing a lyophilized preparation of a cytokine (Noggin) according to any one of claims 1 to 5, characterized in that: The freeze-drying process of the preparation process comprises the following steps: S1: Pre-freezing: First, place the vial containing the sample of the freeze-dried preparation on the freeze dryer partition at 0-5°C for pre-cooling, set 10-30 minutes to reach the preset temperature, maintain for 0.5-1h, cool to -45--40°C, set time 1-2h to reach the preset temperature, maintain for 1-3h to freeze; S2: Sublimation drying: evacuate to 0.1-0.2 mbar, heat to -35℃~-15℃, set time 1~1.5h to reach preset temperature, maintain for 20-50h; S3: Desorption and drying: Heat to 20-35°C, set time 2-3h to reach the preset temperature, maintain 6-10h for desorption and drying, while maintaining vacuum degree 0.1-0.2mbar, freeze drying is completed.

7. The process for preparing the lyophilized preparation of cytokine (Noggin) according to claim 6, characterized in that: The freeze-drying process comprises the following steps: S1: Pre-freezing: First, place the vial containing the sample of the freeze-dried preparation on the freeze dryer partition at 5°C for pre-cooling, set it to reach the preset temperature for 0.5h, maintain it for 1h, cool it down to -45~-40°C, set it to reach the preset temperature for 100min, maintain it for 2h for freezing; S2: Sublimation drying: Heat to -35℃~-15℃, set time 60~80min to reach the preset temperature, maintain for 30h, and maintain vacuum degree 0.1mbar to complete sublimation drying; S3: Desorption and drying: Heat to 20-35°C, set time 150min to reach the preset temperature, maintain for 8h for desorption and drying, while maintaining vacuum degree 0.1mbar, freeze drying is completed.